Centrum Neurologii Krzysztof Selmaj
- Address
- ul. Tylna 12, 90-324 Lodz, Poland
Centrum Neurologii Krzysztof Selmaj - Multiple Sclerosis Research Center
Centrum Neurologii Krzysztof Selmaj is a specialized neurology research center dedicated to advancing the understanding and treatment of neurological disorders, with particular expertise in multiple sclerosis (MS). The center focuses on innovative therapeutic approaches and long-term safety evaluation of emerging treatments for patients with neurological conditions.
- Relapsing multiple sclerosis (RMS) treatment optimization
- Long-term safety and tolerability studies of novel immunomodulatory therapies
- Extended follow-up research for ofatumumab and other disease-modifying treatments
The center is actively involved in open-label extension studies that provide critical real-world evidence on the effectiveness and safety profiles of advanced therapies. Through participation in international clinical trials, Centrum Neurologii Krzysztof Selmaj contributes valuable data on subcutaneous immunotherapies, helping to establish optimal long-term management strategies for patients with relapsing forms of multiple sclerosis.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 therapeutic areas and 15 of 65 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 65 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 5 by active trials.
- 1Tg Therapeutics Inc.2active
lock +4 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1F. Hoffmann-La Roche AG7trials
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centrum Neurologii Krzysztof Selmaj
lock Showing 1 of 18 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase II, Randomized, Open-Label, Parallel Group, Multicenter Study to Assess Bioequivalence of Two Subcutaneous Formulations of Ocrelizumab in Patients with Multiple Sclerosis | F. Hoffmann-La Roche AG | Phase II | Not Recruiting | Dec 2025 | — |
IMP list
lock Showing 1 of 65 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Ocrelizumab | 6 | Unknown | 2018-05-02 | 2026-06-24 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.